Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis

Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical data, and a lack of comparison with paired extracranial specimens. Here we report a cohort of 233 patients with resected an...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 4980 - 11
Main Authors Skakodub, Anna, Walch, Henry, Tringale, Kathryn R., Eichholz, Jordan, Imber, Brandon S., Vasudevan, Harish N., Li, Bob T., Moss, Nelson S., Hei Yu, Kenny Kwok, Mueller, Boris A., Powell, Simon, Razavi, Pedram, Yu, Helena A., Reis-Filho, Jorge S., Gomez, Daniel, Schultz, Nikolaus, Pike, Luke R. G.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 17.08.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2041-1723
2041-1723
DOI10.1038/s41467-023-40793-x

Cover

More Information
Summary:Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical data, and a lack of comparison with paired extracranial specimens. Here we report a cohort of 233 patients with resected and sequenced (MSK-IMPACT) NSCLC BM and comprehensive clinical data. With matched samples (47 primary tumor, 42 extracranial metastatic), we show CDKN2A/B deletions and cell cycle pathway alterations to be enriched in the BM samples. Meaningful clinico-genomic correlations are noted, namely EGFR alterations in leptomeningeal disease (LMD) and MYC amplifications in multifocal regional brain progression. Patients who developed early LMD frequently have had uncommon, multiple, and persistently detectable EGFR driver mutations. The distinct mutational patterns identified in BM specimens compared to other tissue sites suggest specific biologic underpinnings of intracranial progression. The genomic landscape of brain metastasis (BM) in patients with non-small cell lung cancer (NSCLC) remains to be explored. Here, the authors analyse a cohort of 233 patients with BM including 47 primary tumour, 42 extracranial metastatic matched samples and reveal distinct mutational patterns.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-40793-x